PubMed Health⌕ Search

PubMed · 3518924

Therapy for granulomatous angiitis.

Abstract

The clinical diagnosis of granulomatous angiitis can be extremely difficult because of the diversity of presentation. A clinical presentation of progressive multifocal encephalopathy is most common but signs suggesting isolated mass lesions or dementia may be seen. Laboratory studies are helpful, particularly when CSF examination reveals elevated protein or a mononuclear cell response. Cerebral angiogram may demonstrate vasculitis but tissue biopsy is extremely important in firmly establishing a diagnosis. Leptomeningeal biopsy should be performed before initiation of appropriate immunosuppressive therapy and before major irreversible loss of neurologic function occurs. Corticosteroid therapy is the initial treatment of choice, although recent anecdotal reports suggest additional benefits of immunosuppressive drugs such as cytoxan in refractory cases. Whether immunosuppressive drugs should be added routinely cannot be ascertained at present. However, in view of the likelihood of an extended period of treatment, and perhaps relapses when treatment is discontinued, the need to establish an unequivocal diagnosis is of utmost importance when treating with potentially hazardous drugs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E H Koo, E W Massey. 1986. Therapy for granulomatous angiitis.. https://doi.org/10.1097/00002826-198604000-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗